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Individuals with nonalcoholic fatty liver disease (NAFLD) often ask their health care 
providers about routinely consuming non-heavy amounts of alcohol for pleasure and potential health 
benefits. According to the American Association for the Study of Liver Diseases (AASLD) Practice 
Guidance published in 2018, there are insufficient data to make a recommendation with regard to non-
heavy alcohol consumption by individuals with NAFLD.
(1) 
Although several cross-sectional studies 
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have suggested that light alcohol consumption (on average, <1 drink per day) may have a beneficial 
effect on the presence and severity of NAFLD, a large meta-regression analysis suggested that lower 
body mass index among light and moderate drinkers is a potential confounder and thus casts doubt on 
the rigor of those studies.
(2)
 The AASLD Practice Guidance also pointed out that there have been no 
longitudinal studies examining the impact of non-heavy alcohol consumption on the natural history of 
liver disease and its extrahepatic harms and benefits in individuals with established NAFLD. 
Similarly, in a critical review, Ajmera and colleagues concluded that a strong recommendation 
favoring the benefits of moderate alcohol use in NAFLD cannot be made due to significant 
methodological limitations of published studies (e.g., incomplete adjustment for confounders).
(3)
 
 
In this issue of HEPATOLOGY,
(4)
 Chang and colleagues report the results of their study, which 
examined the relationship between non-heavy alcohol consumption and the risk of progression from 
low risk to intermediate and high risk for advanced fibrosis categories based on noninvasive fibrosis 
indices (NAFLD fibrosis score [NFS] FIB-4 and AST-to-platelet ratio index [APRI]) in 57,254 
Korean men and women with NAFLD.
(3)
 After adjusting for potential confounders, compared to 
nondrinkers, light and moderate drinkers were significantly more likely to transition from low risk to 
intermediate or high risk for advanced fibrosis categories. For example, compared to nondrinkers, 
moderate drinkers at low risk for advanced fibrosis at baseline were 40% more likely to transition into 
moderate to high risk for advanced fibrosis category over a median follow-up of 8.3 years. Based on 
these results, the authors concluded that non-heavy alcohol consumption was significantly and 
independently associated with worsening of noninvasive markers of fibrosis, indicating that even 
moderate alcohol consumption might be harmful in individuals with NAFLD. A major limitation of 
this study is that the validity of serial FIB-4 and NFS measurements for characterizing the natural 
history of fibrosis in NAFLD is largely unknown. This observation is corroborated by another 
interesting paper that reported the results of a Mendelian randomization study with rs1229984 G>A 
variant in the alcohol dehydrogenase 1B (ADH1B) gene as a proxy for long-term alcohol exposure 
(individuals with ancestral G allele are likely to drink more, and those with rare A allele are likely to 
drink less).
(5)
 In this study, individuals with NAFLD and ADH1B G/G who drank only 7.5 g of 
alcohol on average per day had significantly higher steatosis, necroinflammation, and NAFLD 
activity score compared to individuals with NAFLD and ADH1B A/G or A/A who drank much less 
alcohol, suggesting that even light alcohol consumption can be associated with more severe liver 
histology in NAFLD. In a paired liver biopsy study from the NASH Clinical Research Network, 
compared to 117 nondrinkers, 168 individuals with modest alcohol use (≤2 drinks per day) were less 
likely to experience spontaneous improvement in liver histology during a mean follow-up of 47 
months between biopsies.
(6)
 Although many studies have shown that the prevalence of NAFLD is 
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lower with moderate alcohol consumption compared to no alcohol consumption in the general 
population, these studies are not directly applicable to patients who have existing NAFLD.
(3)
 
 
Even though there is heightened publicity around the potential benefits of light to moderate 
alcohol drinking on cardiovascular and diabetes risks, the epidemiological evidence linking light 
drinking to increased risk of certain types of solid tumors unfortunately evades any serious scrutiny. 
In a recent meta-analysis consisting of 222 publications and 92,000 light drinkers and 60,000 
nondrinkers with cancers,
(7)
 light drinking was associated with an increased risk for oropharyngeal 
cancer (RR [relative risk], 1.17; 95% CI: 1.06-1.29), esophageal squamous cell cancer (RR, 1:30; 
95% CI: 1.09-1.56), and female breast cancer (RR, 1.05; 95% CI: 1.02-1.08) but not liver (RR, 1.03; 
95% CI: 0.90-1.17) or colorectal cancer (RR, 0.99; 95% CI: 0.96-1.04). In fact, the European Code 
Against Cancer, 4th edition, recommends that “If you drink alcohol of any type, limit your intake. Not 
drinking alcohol is better for cancer prevention.”(8) We believe this recommendation is readily 
applicable to our patients with NAFLD who are at increased risk for cancers because of obesity and 
diabetes, two commonly recognized risk factors for cancers.  
  
Recent trends of alcohol consumption in the United States are quite troubling and yet are not 
receiving sufficient attention. The results from the National Epidemiologic Survey on Alcohol and 
Related Conditions showed that the frequency of high-risk drinking and Diagnostic and Statistic 
Manual of Mental Disorders, 4th Edition (DSM-IV) alcohol use disorder (AUD) has increased by 
29.9% and 49.4%, respectively, between 20012002 and 20122013.
(9)
 While virtually all age, 
geographic, and socioeconomic groups were affected by these increases, striking increases were noted 
in women who exhibited a 58% increase in high-risk drinking and 84% increase in AUD during that 
10-year time frame. According to the National Institute on Alcohol Abuse and Alcoholism 
Surveillance Report No. 105, age-specific death rates from alcohol-related cirrhosis rose dramatically 
between 2009 and 2013 for the first time since 1973.
(10)
 Although the age-adjusted death rate from 
alcohol-related cirrhosis between 2000 and 2013 has increased by 19.1% for white men and 50% for 
white women, it has intriguingly decreased for both black men and women by approximately 32%. 
Tapper and Parikh
(11)
 recently reported that mortality due to alcoholic cirrhosis has been increasing in 
the United States since 2009, with people aged 25 to 34 years exhibiting the greatest increase (average 
annual increase of 10.5% between 2009 and 2016). These sobering trends demand us to be far more 
attentive to the harmful effects of alcohol consumption.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Unless newer data showing a clearly favorable benefit-to-risk ratio of non-heavy drinking in 
individuals with NAFLD become available, the observations by Chang et al.
(4)
 and Ajmera et al.
(6)
 
should compel us to advise our patients with NAFLD against regular consumption of alcohol, even in 
non-heavy amounts, because it is our duty to first do no harm.  
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